Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on January 4, 2022. The filing primarily addresses executive leadership changes and associated compensatory arrangements effective January 1, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: Dr. Akshay K. Vaishnaw's annual base salary as President is set at $725,000 for the 2022 performance year.
- Bonus Target: A target bonus of 60% of the base salary.
- Equity Grant: Non-qualified stock options with a Grant Date fair value of $2,000,000 were granted on December 31, 2021.
- Vesting Schedule: Options vest over four years (25% on the first anniversary, followed by 6.25% quarterly).
Material Changes
The primary material change is the appointment of Akshay K. Vaishnaw, M.D., Ph.D., as President, effective January 1, 2022. Dr. Vaishnaw previously served as President, Research and Development. This appointment follows the earlier promotion of Yvonne L. Greenstreet, MBChB, MBA, to Chief Executive Officer, also effective January 1, 2022.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It serves as a regulatory disclosure of the executive appointment and the accompanying compensation package approved by the People, Culture and Compensation Committee.
Investor Verification Checklist
- Confirm the effective date of Dr. Vaishnaw's promotion to President (January 1, 2022).
- Verify the total value of the equity grant ($2,000,000 fair value) and the specific vesting terms.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.